- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026
The Company will highlight integrated clinical and genomic insights generated through its Oncology Data Solutions platform
Apr. 13, 2026 at 11:08am
Got story updates? Submit your updates here. ›
An abstract visualization of the interconnected forces and insights driving the future of precision oncology research and therapy development.Fort Myers TodayNeoGenomics, Inc., a leading provider of oncology diagnostic solutions, announced it will present eight scientific posters and one oral presentation at the AACR Annual Meeting 2026 in San Diego. The abstracts highlight how combining laboratory testing with clinical data can support oncology research, drive AI-based analysis, and help translate findings into clinically relevant insights.
Why it matters
By linking testing results with real-world clinical data, NeoGenomics has demonstrated its capabilities to drive deeper characterization of biomarker prevalence, evaluation of testing concordance, and insights that help bridge translational research and clinical application, with the potential to enable cutting-edge oncology therapy development and commercialization.
The details
The presentations at AACR will cover a range of topics, including molecular residual disease interception in head and neck cancer, identification of multi-omic biomarkers, characterization of the tumor microenvironment, and detection of genetic alterations in hematologic malignancies and soft tissue sarcomas. These research findings showcase NeoGenomics' ability to leverage its Oncology Data Solutions platform to generate clinically relevant insights that can support oncology therapy development and commercialization.
- The AACR Annual Meeting 2026 will take place from April 17–22, 2026 in San Diego, California.
The players
NeoGenomics, Inc.
A leading provider of oncology diagnostic solutions that enable precision medicine.
Tony Zook
CEO of NeoGenomics.
What they’re saying
“Bringing together lab and clinical data is becoming foundational to modern oncology research. Our collaborations with biopharma partners have allowed us to develop compelling research that we're proud to present at AACR, showcasing how these insights can directly enhance therapy development and create optionality for providers and patients.”
— Tony Zook, CEO
What’s next
Attendees interested in learning more about NeoGenomics' clinical and genomics insight capabilities can connect with the team onsite at booth #1537 during the AACR Annual Meeting 2026.
The takeaway
NeoGenomics' presentation of research at the AACR Annual Meeting 2026 demonstrates the company's ability to leverage its Oncology Data Solutions platform to generate clinically relevant insights that can support the development and commercialization of cutting-edge oncology therapies.
